PROLOR Biotech Announces Closing Of Underwritten Public Offering And Exercise Of Underwriters' Overallotment Option

May 16, 2012, 09:56 ET from PROLOR Biotech, Inc.

NES-ZIONA, Israel, May 16, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH; TASE: PBTH), today announced the closing of its previously announced underwritten public offering.  At the closing, PROLOR issued 7,475,000 shares of its common stock at a price to the public of $5.00 per share, including 975,000 shares issued to the underwriters pursuant to their over-allotment option, which was exercised in full.  The aggregate net proceeds to PROLOR from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $35.0 million.

Jefferies & Company, Inc. acted as the sole book-running manager and Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS), and Oppenheimer & Co. Inc. acted as co-managers for the offering.

The offering was made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission, or SEC, which the SEC declared effective on April 26, 2012.  Copies of a final prospectus supplement relating to the offering, which has been filed with the SEC, may be obtained by sending a request to the offices of Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by telephone at 877 547-6340, or by email at, or to Ladenburg Thalmann & Co. Inc., 520 Madison Avenue, 9th Floor, New York, NY 10022, or by telephone at 212 409-2000, or by email at, or to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at 212 667-8563, or by email at

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


PROLOR Biotech, Inc. is a development stage biopharmaceutical company utilizing patented technology to develop longer-acting, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales.



Investor Relations 

Barbara Lindheim

PROLOR Biotech, Inc. 

BLL Partners, LLC

Tel: +1 866 644-7811 

+1 212 584-2276